Petrelintide, a nascent form of treatment known as an amylin analog, adds to Roche's existing GLP-1 offering including CT-388 and once-daily oral candidate CT-996, which were both acquired as part of Roche's first foray into the obesity market with the purchase in late 2023 of U.S
orlistat with gastrointestinal effects and interference with fat-soluble vitamin absorption
These research-stage amylin-based candidates differ in receptor focus, molecular design, clinical evidence, side-effect profile, and development strategy
Assuming a 4-week renewal cycle, this suggests a current count of fully committed patients of about 8 million Americans
This self-massage technique can help to release built-up tension in your back, legs, and shoulders, providing instant relief
What is 5-Amino-1MQ